Jim Cramer fired a triple buy call Aug. 11 on the “Mad Money” Lightning Round. It came for a stock most people still have not heard of.
He backed it up with four words that tell you exactly why. Let’s see where he finds that conviction call.
[Buy, buy, buy]. What a quarter they had.
Hinge Health (HNGE) has surged 85.83% year to date, according to Yahoo Finance. That’s after hitting a fresh all-time high of $93.13 on Aug. 10.
On top of that, Hinge reported record second-quarter 2026 results on Aug. 4, growing revenue 53% year over year to $213 million, tripling free cash flow to nearly $100 million, and raising full-year guidance.
Then it announced a $105 million acquisition to expand into gastrointestinal care. For a company most investors know nothing about, the numbers behind the business are genuinely impressive.
What Hinge Health actually does and why the market is paying attention
Hinge Health was founded in 2014 by Daniel Perez and Gabriel Mecklenburg, both of whom had personal experiences with musculoskeletal (MSK) injuries and the frustrating recovery process that followed.
The company built an artificial intelligence (AI)-powered platform that delivers automated, personalized MSK care — covering chronic pain, acute injury, and post-surgical rehabilitation — at scale through enterprise employers and health plans.
More Jim Cramer:
- Jim Cramer has terrifying one-word message for tech stock investors
- Jim Cramer says he’s steering clear of one popular stock
- Jim Cramer reveals 4 surging chip stocks he likes best
The business model targets the MSK market from the employer side, not the consumer side.
Corporations and health plans pay Hinge Health to provide their covered populations with digital physical therapy and care management, reducing downstream medical costs on conditions that are among the most expensive to treat in U.S. health care.
As of June 30, 2026, Hinge Health serves 2,929 clients, up 24% year over year, including more than half of the Fortune 100, according to its Q2 earnings release. The Last Twelve Months (LTM) calculated billings reached $861.8 million, up 52% year over year.
The Hinge Health Q2 results that made Cramer say “what a quarter”
The second-quarter financial performance was strong across every metric that matters for a growth company.
- Revenue of $213 million grew 53% year over year (YoY).
- Non-GAAP operating income of $61.5 million more than doubled YoY
- Non-GAAP operating margin expanded to 29% from 19% in Q2 2025.
- Free cash flow of $99.6 million grew 3x from $32.6 million in the prior year period, with a free cash flow margin of 47%.
Source: Hinge Health Second-Quarter 2026 Results
The free cash flow acceleration is the detail that stands out most to me.
Why? A company growing revenue 53% while simultaneously tripling free cash flow and expanding operating margins is demonstrating genuine business leverage.
That’s the kind that makes growth look sustainable rather than bought. Full-year 2026 guidance was raised to $856 million to $860 million, reflecting 46% year-over-year growth at the midpoint.
Non-GAAP income from operations guidance was raised to $236 million to $244 million, representing 101% year-over-year growth. For Q3, the company guided revenue of $223 million to $225 million, up 45% year over year.
Avishek Das/SOPA Images/LightRocket via Getty Images
Hinge expands beyond musculoskeletal care
The most strategically interesting part of Hinge Health’s 2026 story is not the core MSK business that is performing well. It is the platform expansion into adjacent conditions.
First, its Migraine Care Program, launched in April 2026, already has more than 450 clients signed up and covers more than 5 million lives, according to The Motley Fool Q2 2026 earnings call transcript.
That adoption speed for a new product line is proof that the existing enterprise client base is willing to expand its relationship with Hinge Health across conditions.
Related: Jim Cramer sees the writing on the wall for SpaceX investors
Second, the Cylinder Health acquisition, confirmed the same day as Q2 results, extends the platform into gastrointestinal care. The $105 million cash deal brings nearly 100 enterprise clients, 2 million covered lives, and partnerships with two of the three largest pharmacy benefit managers, as well as three of the top five health plans by self-insured market share.
The strategic logic is compelling. GI conditions affect approximately one in four U.S. adults and represent $135 billion in annual medical spending. A surprising 69% of U.S. counties lack a gastroenterologist, creating the same access gap MSK care has, according to a Hinge Health report.
Chronic GI issues frequently co-occur with the musculoskeletal and migraine conditions Hinge Health already treats. An integrated multi-condition platform in a single app — targeted for 2027 — makes the enterprise value proposition significantly broader.
What the Hinge Health buyback expansion tells you
The board approved a $300 million increase to the share repurchase program on July 29, bringing total authorized repurchases to approximately $496.5 million, according to the Q2 earnings report. Hinge has already repurchased $196.5 million in shares.
I think for a company growing 50%-plus with 47% free cash flow margins, aggressively buying back stock signals confidence in the business trajectory.
It also means the dilution risk that plagues many growth companies is being actively managed. Those are a few more reasons to entertain that buy call.
Cramer’s triple-buy call on a stock up 85% year to date reflects his read that Q2 results and the expansion into migraine and GI care represent a business compounding faster than its market position implies.
The numbers on Aug. 4 gave him the evidence. The Cylinder acquisition gave him the platform story. Put together, I see the case building for Hinge Health as more than a niche digital health name.
Related: Jim Cramer makes bold call on controversial fintech stock
